105 completed, 79 recruiting, 55 unknown, 45 not yet recruiting. 327 Phase 3, 65 Phase 2.
Follow Ischemic Stroke: new trials by email Literature Review of Ischemic Stroke trials Research Report on Ischemic Stroke
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant Intravenous tenecteplase (TNK), Placebo - Acute Ischemic Stroke | Phase 3 | Not yet recruiting | Hackensack Meridian Health | 660 | 2027-01-01 | 2026-06-02 |
| INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 Mechanical Endovascular Thrombectomy, Intravenous Thrombolysis, Tenecteplase/Alteplase- depending upon availability at each treating centre - Stroke, Acute Ischemic, Medium Vessel Occlusion | Phase 3 | Not yet recruiting | University of Calgary | 800 | 2026-12-15 | 2026-10-30 |
| Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial Intelligence Recombinant Human Prourokinase for Injection (rhPro-UK), Matching Placebo for Recombinant Human Prourokinase - Acute Ischemic Stroke | Phase 3 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 826 | 2026-12-01 | 2026-10-28 |
| A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants Cenvacibart, Placebo - Secondary Stroke | Phase 3 | Not yet recruiting | Regeneron Pharmaceuticals | 6106 | 2026-11-20 | 2026-10-15 |
| A Multicenter, Three-Arm, Open-Label, Endpoint-Blinded Randomized Controlled Trial to Evaluate the Optimal Duration of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke Tirofiban Injection, No Interventions - Acute Ischemic Stroke | Phase 2 / Phase 3 | Not yet recruiting | Xinqiao Hospital of Chongqing | 1482 | 2026-11-19 | 2026-09-25 |
| Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial Edoxaban 15 mg, Aspirin or clopidogrel - Stroke, Ischemic | Phase 3 | Recruiting | Sunnybrook Health Sciences Centre | 1204 | 2026-11-01 | 2026-10-23 |
| Metformin in Acute Ischemic Stroke Placebo, Metfomin - Acute Ischemic Stroke | Phase 3 | Not yet recruiting | All India Institute of Medical Sciences | 440 | 2026-11-01 | 2026-10-29 |
| Tenecteplase or Reteplase as Bridging Thrombolysis Before Thrombectomy in Acute Ischemic Cerebrovascular Events rhTNK-tPA (0.25mg/kg), Reteplase 10 Units (U) plus a second dose of reteplase 10 U, No thrombolysis (thrombectomy alone) - Acute Ischemic Stroke, Large Vessel Occlusion | Phase 3 | Recruiting | Yongjun Wang | 1440 | 2026-10-16 | 2026-10-22 |
| Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke Zastaprazan, Placebo - Ischemic Stroke, Transient Ischemic Attack | Phase 3 | Not yet recruiting | Asan Medical Center | 984 | 2026-10-15 | 2026-10-09 |
| Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stroke Recombinant Human Prourokinase for Injection (rhPro-UK), Standard medical treatment (SMT) - Acute Ischemic Stroke | Phase 3 | Recruiting | The First Affiliated Hospital of Anhui Medical University | 616 | 2026-10-06 | 2026-10-07 |
| Cilostazol for Prevention of Recurrent Stroke Trial Cilostazol 100 mg Tablets, Placebo - Stroke Recurrence, Myocardial Infarction | Phase 3 | Not yet recruiting | Stanford University | 2000 | 2026-10-01 | 2026-10-26 |
| A Phase 3 Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After Acute Ischemic Stroke LNM-navigated cTBS, Sham cTBS - Ischemic Stroke | Phase 3 | Not yet recruiting | Beijing Tiantan Hospital | 584 | 2026-10-01 | 2026-08-18 |
| Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS) Rivaroxaban, ASA - Ischemic Stroke, Intracranial Atherosclerosis | Phase 3 | Not yet recruiting | Population Health Research Institute | 1172 | 2026-09-30 | 2026-09-01 |
| Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg), Standard medical treatment - Acute Ischemic Stroke, Tenecteplase | Phase 3 | Recruiting | First Affiliated Hospital of Guangxi Medical University | 352 | 2026-09-24 | 2026-09-30 |
| Infarct Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy - ILLUMINATE Tociliuzumab, Placebo - Acute Ischemic Stroke | Phase 2 / Phase 3 | Not yet recruiting | Oslo University Hospital | 156 | 2026-09-21 | 2026-10-13 |
| Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial Tirzepatide, Standard Medical Care (SMC) - Acute Ischemic Stroke (AIS) | Phase 2 / Phase 3 | Not yet recruiting | yifang zhu | 726 | 2026-09-20 | 2026-10-01 |
| Intra-arterial Thrombolysis For Acute Ischemic Stroke With Medium Vessel Occlusion Recombinant Tissue Plasminogen Activator (rt-PA), Intra-arterial Thrombolysis, Best Medical Management - Medium Vessel Occlusion, Ischemic Stroke, Acute | Phase 3 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 372 | 2026-09-19 | 2026-09-23 |
| Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy glenzocimab, placebo - Acute Ischemic Stroke | Phase 2 / Phase 3 | Withdrawn | Fondation Ophtalmologique Adolphe de Rothschild | 2026-09-01 | 2026-09-09 | |
| Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy Rivaroxaban, or Edoxaban , or Apixaban , or Dabigatran, Aspirin - Stroke, Acute Ischemic Stroke | Phase 3 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 680 | 2026-08-15 | 2026-08-05 |
| ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 Tenecteplase or Alteplase- depending upon availability at each treating centre, Control - Stroke, Acute Ischemic, Endovascular Thrombectomy | Phase 3 | Recruiting | University of Calgary | 1500 | 2026-08-11 | 2026-10-21 |
Showing 20 of 327. Sign in to see all of them.
Stroke (106) · Cerebrovascular Disorders (10) · Ischemic Attack, Transient (10) · Cerebral Infarction (9) · Brain Ischemia (8) · Atrial Fibrillation (6) · Brain Diseases (6) · cyclopia sequence (6) · Brain Infarction (5) · Carotid Stenosis (5) · Ischemia (5) · Recurrence (5) · Stroke, Lacunar (5) · Atherosclerosis (4)
Nervous System Diseases (325) · Cardiovascular Diseases (324) · Central Nervous System Diseases (324) · Vascular Diseases (324) · Brain Diseases (321) · Cerebrovascular Disorders (317) · Stroke (221) · Pathological Conditions, Signs and Symptoms (52) · Pathologic Processes (43) · Brain Ischemia (22) · Infarction (21) · Necrosis (21) · Ischemia (19) · Arterial Occlusive Diseases (13) · Brain Infarction (13)
Tenecteplase (37) · Aspirin (34) · Clopidogrel (26) · Tissue Plasminogen Activator (22) · Ticagrelor (14) · Tirofiban (13) · Cilostazol (11) · Injections (8) · Saline Solution (8) · Minocycline (7) · Rivaroxaban (7) · Sodium Chloride (6) · Atorvastatin (5) · apixaban (5) · tocilizumab (5)
Beijing Tiantan Hospital (26) · Kafrelsheikh University (18) · Capital Medical University (12) · Second Affiliated Hospital, Zhejiang University, School of Medicine (10) · Assistance Publique - Hôpitaux de Paris (8) · Xiang Luo (7) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (6) · General Hospital of Shenyang Military Region (5) · University of Calgary (5) · Xinqiao Hospital of Chongqing (5) · Peking Union Medical College Hospital (4) · Dexa Medica Group (3) · Mazandaran University of Medical Sciences (3) · Neuroscience Trials Australia (3) · Samsung Medical Center (3)
China (125) · United States (45) · Canada (25) · France (24) · Spain (23) · Egypt (21) · Germany (21) · South Korea (19) · Australia (17) · Switzerland (15) · United Kingdom (13) · Russia (11) · Sweden (11) · Brazil (10) · Finland (10)
Yongjun Wang (5) · Min Lou, PhD, MD (4) · Raul G Nogueira, MD (4) · Xiang Luo (4) · Yamei Tang (4) · Masayasu Matsumoto, MD, PhD (3) · Oh Young Bang, MD (3) · Sheila CO Martins, MD, PhD (3) · Yilong Wang, MD, PhD (3) · Yongjun Wang, MD (3) · Zhongming Qiu, MD (3) · Bijoy K Menon, MD (2) · Bin Peng, MD (2) · Brian Silver, MD (2)
PMID 31867054, PMID 18190818, PMID 2375765, PMID 34515113, PMID 16731270, PMID 21899409, PMID 34487721, PMID 12807523, PMID 26898852, PMID 31067369, PMID 31662037, PMID 33588596, PMID 24168957, PMID 25671797, PMID 25671798, PMID 25882510, PMID 26387127, PMID 28052979, PMID 29127270, PMID 29766770, PMID 30045949, PMID 30523735, PMID 31570084, PMID 32905623, PMID 33464335, PMID 34418399, PMID 34786868, PMID 35224730, PMID 35943471, PMID 36398903, PMID 37256974, PMID 37830342, PMID 38648030, PMID 39147573, PMID 39500603, PMID 41500725, PMID 42100960, PMID 11306611, PMID 11315017, PMID 11673584, PMID 11914403, PMID 12271462, PMID 15800226, PMID 16614616, PMID 16899775, PMID 17050890, PMID 17290030, PMID 17702958, PMID 18032739, PMID 18235078
2023 (4), 2008 (2), 2016 (2), 2017 (2), 2018 (2), 2025 (2), U01NS054630 (2), 1UG3NS133209-01A1 (1), 2014 (1), R01NR017850 (1), R01NS077706 (1), U01NS052220 (1), U01NS058728 (1), U01NS069498 (1), U01NS095869 (1)